Avadel Pharmaceuticals PLC is required to pay a 3.85% ongoing royalty on sales of LUMRYZ to Jazz Pharmaceuticals, effective from September 15, 2025, due to a court ruling regarding patent infringement. Avadel plans to contest this ruling while recognizing the royalty obligations on their balance sheet.